Endocrine Surgery

Obtain high-resolution nodal ultrasound (assessing loss of fatty hilum, round shape, cortical thickening >3 mm, peripheral vascularity) plus ultrasound-guided core-needle biopsy (14–16G) for rapid triage. If lymphoma is suspected or core biopsy is non-diagnostic, perform complete excisional biopsy of the largest intact abnormal node — sending tissue fresh in saline (for flow cytometry/cytogenetics) AND in formalin (for architecture/IHC), plus AFB/GeneXpert for tuberculous lymphadenitis.

Before: Empiric multiple courses of antibiotics, blind open biopsy of a metastatic squamous cervical node before panendoscopy, or relying on FNA cytology alone to rule out lymphoma.

Now: Obtain high-resolution nodal ultrasound (assessing loss of fatty hilum, round shape, cortical thickening >3 mm, peripheral vascularity) plus ultrasound-guided core-needle biopsy (14–16G) for rapid triage. If lymphoma is suspected or core biopsy is non-diagnostic, perform complete excisional biopsy of the largest intact abnormal node — sending tissue fresh in saline (for flow cytometry/cytogenetics) AND in formalin (for architecture/IHC), plus AFB/GeneXpert for tuberculous lymphadenitis.

Patients with persistent unexplained cervical, axillary, or inguinal lymphadenopathy (>2–4 weeks, >1.5–2.0 cm, or constitutional B-symptoms), exactly as the addendum's summary row states the thresholds.

WHO lymphoma subclassification requires intact nodal architecture, immunophenotyping, and flow cytometry — FNA alone cannot carry the diagnosis. Open biopsy of a solitary metastatic neck node before upper aerodigestive evaluation worsens regional neck recurrence; the printed sequence (image, core, then intact excision when indicated) is the practice change.

• NCCN Hodgkin/Non-Hodgkin Lymphoma & Head and Neck Guidelines — as cited in the addendum summary table (no PMID printed)

Obtain preoperative ultrasound-guided FNA (classified by the Milan System for Reporting Salivary Gland Cytopathology) plus multiphasic MRI (or contrast CT). Perform superficial parotidectomy or extracapsular dissection with a cuff of normal parenchyma under facial nerve magnification and neuromonitoring — and total parotidectomy plus selective neck dissection for high-grade mucoepidermoid or adenoid cystic carcinoma, or nodal metastasis.

Before: Open incisional biopsy or simple enucleation ('shelling out') of a parotid pleomorphic adenoma.

Now: Obtain preoperative ultrasound-guided FNA (classified by the Milan System for Reporting Salivary Gland Cytopathology) plus multiphasic MRI (or contrast CT). Perform superficial parotidectomy or extracapsular dissection with a cuff of normal parenchyma under facial nerve magnification and neuromonitoring — and total parotidectomy plus selective neck dissection for high-grade mucoepidermoid or adenoid cystic carcinoma, or nodal metastasis.

Patients with benign and malignant parotid and submandibular salivary gland neoplasms, exactly as the addendum's summary row states them.

Enucleation or open biopsy of pleomorphic adenoma ruptures pseudopodia across the capsule, increasing multifocal recurrence from <2% to 20–45% and risking facial nerve injury — the no-enucleation rule is the safety core of this change.

• ASCO / NCCN Salivary Gland Malignancy Guidelines — as cited in the addendum summary table (no PMID printed)
• Milan System for Reporting Salivary Gland Cytopathology — as cited in the addendum summary table (no PMID printed)

Radiofrequency or microwave ablation is an established scarless outpatient option for symptomatic, twice-biopsy-confirmed benign (Bethesda II) solid thyroid nodules, per the 2020 European Thyroid Association guideline the book cites — present it in counselling alongside surgery for this defined population.

Before: Symptomatic benign thyroid nodules were counselled toward surgical excision (lobectomy or thyroidectomy) as the definitive procedural option, without ablation in the routine offer (converse of the book's printed §5.4 position — §5.4 prints no outdated-routine cell).

Now: Radiofrequency or microwave ablation is an established scarless outpatient option for symptomatic, twice-biopsy-confirmed benign (Bethesda II) solid thyroid nodules, per the 2020 European Thyroid Association guideline the book cites — present it in counselling alongside surgery for this defined population.

Patients with symptomatic, twice-biopsy-confirmed benign (Bethesda II) solid thyroid nodules, exactly as §5.4 item 3 states the population.

Do not extend this card to cancer: thermal ablation for T1a papillary microcarcinoma is classed investigational in the same §5.4 item and is reserved for selected nonsurgical candidates or clinical protocols; long-term (10-year) comparative studies of ablation vs. active surveillance or lobectomy in T1a disease remain an open controversy (§5.6). §5.4 groups selected TOETVA with this item as an early-adoption remote-access approach; this card takes no position on it beyond that grouping.

• 2020 ETA Thermal Ablation Guideline — Mauri G et al., Eur Thyroid J 2020 (PMID 32903999; Ref. 91)

Obtain preoperative neck ultrasound (to confirm a normal orthotopic thyroid gland and exclude an ectopic median thyroid); control any acute cyst infection with antibiotics/aspiration first; then perform a formal Sistrunk procedure — excising the cyst, the tract, the central third of the hyoid bone body, and a core of suprahyoid musculature to the foramen cecum. For second branchial cleft cysts, perform complete excision along the anterior border of the sternocleidomastoid through the carotid bifurcation to the tonsillar fossa.

Before: Simple cystectomy (enucleation) of a thyroglossal duct cyst without removing the central hyoid bone, or incision and drainage of an uninfected branchial cyst.

Now: Obtain preoperative neck ultrasound (to confirm a normal orthotopic thyroid gland and exclude an ectopic median thyroid); control any acute cyst infection with antibiotics/aspiration first; then perform a formal Sistrunk procedure — excising the cyst, the tract, the central third of the hyoid bone body, and a core of suprahyoid musculature to the foramen cecum. For second branchial cleft cysts, perform complete excision along the anterior border of the sternocleidomastoid through the carotid bifurcation to the tonsillar fossa.

Patients with a congenital midline thyroglossal duct cyst (TGDC) and patients with a lateral second branchial cleft cyst, exactly as the addendum's summary row states them.

Simple cystectomy of a thyroglossal duct cyst carries a 38–50% recurrence rate, whereas the Sistrunk operation lowers recurrence to <3–4% — the hyoid-and-tract excision is the practice change, not an optional refinement. The preoperative ultrasound step (normal orthotopic thyroid present) is a safety gate before any midline excision.

• Head & Neck Endocrine Surgical Consensus Guidelines — as cited in the addendum summary table (no PMID printed)

Pair imaging phenotype (homogeneous unenhanced CT <=10 HU confirms benign lipid-rich adenoma) with targeted endocrine testing per ESE/ENSAT 2023: (1) 1-mg overnight dexamethasone suppression test in all adrenal incidentalomas (cortisol >1.8 mcg/dL [50 nmol/L] without overt Cushing features defines MACS, managed by multidisciplinary assessment of comorbidities, age, and cortisol autonomy rather than automatic surgery); (2) plasma or urinary metanephrines in any lesion NOT showing typical benign unenhanced CT <=10 HU or with adrenergic symptoms; (3) aldosterone-to-renin ratio if hypertensive/hypokalemic; and (4) mandatory alpha-blockade before beta-blockade in pheochromocytoma.

Before: Using unenhanced CT <=10 HU as the sole evaluation without hormonal testing, restricting metanephrines only to selected >10 HU cases without clear criteria, recommending adrenalectomy for all MACS, or starting beta-blockers before alpha-blockade.

Now: Pair imaging phenotype (homogeneous unenhanced CT <=10 HU confirms benign lipid-rich adenoma) with targeted endocrine testing per ESE/ENSAT 2023: (1) 1-mg overnight dexamethasone suppression test in all adrenal incidentalomas (cortisol >1.8 mcg/dL [50 nmol/L] without overt Cushing features defines MACS, managed by multidisciplinary assessment of comorbidities, age, and cortisol autonomy rather than automatic surgery); (2) plasma or urinary metanephrines in any lesion NOT showing typical benign unenhanced CT <=10 HU or with adrenergic symptoms; (3) aldosterone-to-renin ratio if hypertensive/hypokalemic; and (4) mandatory alpha-blockade before beta-blockade in pheochromocytoma.

Adults with an adrenal incidentaloma (>=1 cm) or functional adrenal neoplasm. Outcomes rated in the matrix: malignancy exclusion, hormonal cure, and perioperative hemodynamic safety.

ESE/ENSAT 2023 notes that homogeneous adrenal lesions with unenhanced CT <=10 HU have a near-zero risk of pheochromocytoma or adrenocortical carcinoma, whereas any lesion with unenhanced CT >10 HU (or unmeasured unenhanced HU) requires biochemical exclusion of pheochromocytoma and second-line imaging/MDT evaluation. In MACS, verify ACTH independence (suppressed/low morning plasma ACTH) and assess potentially attributable comorbidities (hypertension, type 2 diabetes, dyslipidemia, vertebral fractures/osteoporosis); adrenalectomy is NOT indicated for every patient with MACS — surgery is considered selectively through multidisciplinary shared decision-making (progressive or difficult-to-control metabolic/cardiovascular/bone comorbidities, younger physiological age, unilateral adenoma, more pronounced cortisol autonomy), with mandatory perioperative glucocorticoid stress coverage and postoperative HPA-axis recovery monitoring (§5.2). Sex hormones and steroid precursors are measured when adrenocortical carcinoma or virilization is suspected (§5.2). Mandatory alpha-first rule (§5.0 Guardrail 3): in confirmed or suspected pheochromocytoma/paraganglioma, alpha-adrenergic blockade (10–14 days) and volume expansion supervised by an experienced endocrine and anesthesia team must ALWAYS precede any beta-adrenergic blocker, to prevent unopposed alpha-mediated hypertensive crisis and pulmonary edema.

Regional layer (§5.2 Saudi & Gulf frame): Saudi practice applies the international 2025 ATA and 2023 ESE/ENSAT guidelines alongside two formal GCC regional consensus publications — neither a high-certainty randomized trial nor a statutory national mandate. The 2025 GCC Delphi Consensus on Cushing's Disease & Adrenalectomy (Almalki, Alzahrani et al., Front Endocrinol 2025; PMID 41098590) supports referral to high-volume pituitary/endocrine centers and reserves bilateral laparoscopic adrenalectomy as a rescue option for severe refractory ACTH-dependent hypercortisolism, with lifelong glucocorticoid and mineralocorticoid replacement.

• 2023 ESE / ENSAT Adrenal Incidentaloma Clinical Practice Guidelines — Fassnacht et al., Eur J Endocrinol 2023 (PMID 37318239)
• 2025 GCC Delphi Consensus on Cushing's Disease & Adrenalectomy — Almalki, Alzahrani et al. (PMID 41098590)

Where available and clinically appropriate, reflex molecular testing (e.g., ThyroSeq v3 or Afirma GSC) informs clinical decision-making alongside ultrasound phenotype (ACR TI-RADS), nodule size, and patient preference. If surgery is performed and NIFTP is suspected, low-risk NIFTP classification requires complete histopathological sampling of the entire tumor capsule and strict exclusion criteria.

Before: Treating molecular test NPV (96%–97%) as a universal constant independent of pretest malignancy prevalence, or implying NIFTP can be diagnosed on cytology alone.

Now: Where available and clinically appropriate, reflex molecular testing (e.g., ThyroSeq v3 or Afirma GSC) informs clinical decision-making alongside ultrasound phenotype (ACR TI-RADS), nodule size, and patient preference. If surgery is performed and NIFTP is suspected, low-risk NIFTP classification requires complete histopathological sampling of the entire tumor capsule and strict exclusion criteria.

Adults with Bethesda III [AUS] and Bethesda IV [Follicular Neoplasm] thyroid nodules. Outcomes rated in the matrix: diagnostic surgery avoidance and histopathological verification of NIFTP.

In prospective multicenter validation cohorts with pretest malignancy prevalence of ~24%–28%, ThyroSeq v3 (Steward et al., JAMA Oncol 2019; n = 257) and Afirma GSC (Patel et al., JAMA Surg 2018; n = 190) demonstrated negative predictive values of 96%–97% and benign call rates of 54%–61% (sparing ~60%–65% of indeterminate nodules from diagnostic lobectomy). Because NPV and benign call rate depend on local cancer prevalence and cytology mix, molecular results complement rather than replace clinical judgment. Strict NIFTP criteria (§5.2): encapsulated or sharply demarcated follicular-patterned lesion, nuclear score 2–3, complete absence of capsular or vascular invasion, <1% true papillae, no psammoma bodies, no tumor necrosis, <3 mitoses per 10 HPF, and absence of BRAF V600E or other high-risk mutations; if any criterion is violated, the lesion is managed as invasive differentiated thyroid carcinoma (§5.5).

Author-proposed regional adaptation (§5.2 Saudi & Gulf frame): because send-out molecular cytology (ThyroSeq v3 / Afirma GSC) is not uniformly reimbursed across all Saudi hospitals, clinicians should integrate ACR TI-RADS ultrasound features into local perioperative pathways.

• 2023 Bethesda System for Reporting Thyroid Cytopathology, 3rd Ed. — Ali et al. (PMID 37427847)
• 2025 ATA Differentiated Thyroid Cancer Guidelines (PMID 40844370)
• Steward et al. 2019 (ThyroSeq v3) — as cited in Table 5.1
• Patel et al. 2018 (Afirma GSC) — as cited in Table 5.1

Individualized shared decision-making between initial thyroid lobectomy and total thyroidectomy based on tumor size/location, ultrasound features, contralateral lobe status, molecular profile, patient preference regarding surveillance vs. a potential two-stage operation, and whether postoperative RAI may be indicated.

Before: Presenting either total thyroidectomy or thyroid lobectomy as a universal rule for all 2–4 cm tumors without shared decision-making.

Now: Individualized shared decision-making between initial thyroid lobectomy and total thyroidectomy based on tumor size/location, ultrasound features, contralateral lobe status, molecular profile, patient preference regarding surveillance vs. a potential two-stage operation, and whether postoperative RAI may be indicated.

Adults with unilateral intrathyroidal cT2 (>2–4 cm) cN0 M0 DTC. Outcomes rated in the matrix: overall survival, structural recurrence, and need for completion thyroidectomy.

In the NCDB multivariable analysis (Adam et al., Ann Surg 2014; n = 61,775 PTC 1–4 cm), overall survival did not differ significantly between lobectomy and total thyroidectomy for 2.1–4.0 cm tumors (HR 1.05, 95% CI 0.91–1.22; p = 0.54). However, survival is distinct from the need for a second operation: in institutional surgical series of clinically low-risk 1–4 cm / cT2 cN0 patients undergoing initial lobectomy (e.g., Kluijfhout et al., Ann Surg 2016; Vaisman et al.), ~15%–20% (and up to 30%–40% under stricter historical criteria) had unexpected pathological features (angioinvasion, microscopic ETE, aggressive histology, or occult positive nodes) that prompted discussion of completion thyroidectomy.

• 2025 ATA Differentiated Thyroid Cancer Guidelines — Ringel et al., Thyroid 2025 (PMID 40844370)
• Adam et al., Ann Surg 2014 (PMID 25203876)

Initial thyroid lobectomy (without routine prophylactic central neck dissection or routine RAI) for appropriately selected unilateral, intrathyroidal, cN0 DTC <=2.0 cm when exclusions are absent (no gross extrathyroidal extension, nodal/distant metastasis, contralateral nodules requiring surgery, prior head/neck radiation, familial thyroid cancer, or separate indication for RAI).

Before: Routine total thyroidectomy with prophylactic central neck dissection and empiric radioactive iodine (RAI) remnant ablation for all DTC <=2.0 cm.

Now: Initial thyroid lobectomy (without routine prophylactic central neck dissection or routine RAI) for appropriately selected unilateral, intrathyroidal, cN0 DTC <=2.0 cm when exclusions are absent (no gross extrathyroidal extension, nodal/distant metastasis, contralateral nodules requiring surgery, prior head/neck radiation, familial thyroid cancer, or separate indication for RAI).

Adults with unilateral intrathyroidal cN0 DTC <=2.0 cm without gross extrathyroidal extension. Outcomes rated in the matrix: overall survival, disease-specific survival, recurrence, need for completion thyroidectomy, and hypoparathyroidism/RLN injury.

Separating distinct endpoints: overall survival and disease-specific survival do not differ between lobectomy and total thyroidectomy in low-risk cT1 cN0 cohorts, while lobectomy avoids contralateral RLN risk and permanent hypoparathyroidism. Preserving endogenous euthyroidism without levothyroxine occurs in ~70%–80% overall in surgical series (e.g., Verloop et al., JCEM 2012; Park et al.), but ranges from >85% when preoperative TSH is <2.0 mIU/L without thyroiditis to <40%–50% when preoperative TSH is >2.5 mIU/L or anti-TPO antibodies are positive. NCDB multivariable Cox analysis (n = 61,775) showed a null OS difference (HR 0.96, 95% CI 0.84–1.09, p = 0.54).

• 2025 ATA Differentiated Thyroid Cancer Guidelines — Ringel et al., Thyroid 2025 (PMID 40844370)
• Adam et al. NCDB Analysis, Ann Surg 2014 (PMID 25203876)

Use device-specific IONM protocols as an adjunct to visual nerve identification and apply the full INMSG troubleshooting and staging algorithm after first-side loss of signal. Separate NIRAF (parathyroid tissue identification; reduces transient hypocalcemia in PARAFLUO) from ICG angiography (vascular perfusion). In PHPT with negative/discordant initial US + Sestamibi, select 4D-CT, 18F-fluorocholine PET/CT, MRI, or bilateral exploration by local expertise, radiation/contrast considerations, and whether localization alters the operative plan.

Before: Using a universal EMG microvolt cutoff across devices, equating NIRAF with perfusion assessment or guaranteed permanent normocalcemia, or treating 4D-CT as the mandatory default for every discordant parathyroid case.

Now: Use device-specific IONM protocols as an adjunct to visual nerve identification and apply the full INMSG troubleshooting and staging algorithm after first-side loss of signal. Separate NIRAF (parathyroid tissue identification; reduces transient hypocalcemia in PARAFLUO) from ICG angiography (vascular perfusion). In PHPT with negative/discordant initial US + Sestamibi, select 4D-CT, 18F-fluorocholine PET/CT, MRI, or bilateral exploration by local expertise, radiation/contrast considerations, and whether localization alters the operative plan.

Adults undergoing thyroidectomy or parathyroidectomy, and patients with primary hyperparathyroidism requiring localization. Outcomes rated in the matrix: vocal cord function, transient (<6 mo) vs. permanent (>=6 mo) hypoparathyroidism, and parathyroid adenoma localization.

IONM is an adjunct to visual recurrent laryngeal nerve identification and meticulous capsular dissection, not a guarantee against RLN injury; do not apply a single universal microvolt cutoff across different commercial systems — follow the manufacturer's and institution's validated loss-of-signal troubleshooting algorithm (checking endotracheal tube electrode position via laryngoscopy, neuromuscular blockade, hardware connections, and vagal V1/R1/R2/V2 stimulation) (§5.0 Guardrail 1). After confirmed true unilateral LOS on the first side, staging the contralateral side (coupled with postoperative laryngoscopy) is a core safety principle in bilateral benign or low-risk differentiated thyroid surgery; urgent locally invasive oncologic scenarios require individualized specialist judgment. In PARAFLUO (n = 241), NIRAF lowered temporary hypocalcemia (<8.0 mg/dL on POD 1–2: 9.1% [11/121] vs. 21.7% [26/120]; difference 12.6%, 95% CI 5.0%–20.1%; P = 0.007; aOR 0.35), inadvertent parathyroid resection (2.5% vs. 11.7%; P = 0.006), and autotransplantation (3.3% vs. 13.3%; P = 0.009), but permanent hypoparathyroidism at 6 months did not differ significantly (0% vs. 1.7%; P = 0.15). Neither NIRAF nor ICG guarantees postoperative parathyroid function or permanent normocalcemia (§5.0 Guardrail 2). In PHPT, negative localization imaging never rules out biochemical diagnosis or surgical indication.

• INMSG Standards Guideline — Randolph et al., Laryngoscope 2011 (PMID 21181860)
• PARAFLUO RCT — Benmiloud et al., JAMA Surg 2020 (PMID 31693081)
• AAES Parathyroidectomy Guidelines — Wilhelm et al., JAMA Surg 2016 (PMID 27532368)
• Fifth International Workshop on PHPT — Bilezikian et al., J Bone Miner Res 2022 (PMID 36245251)

Shared decision-making between structured active ultrasound surveillance (neck US every 6 months for 1–2 years, then annually) and initial thyroid lobectomy in strictly eligible patients; exclude active surveillance if subcapsular tumor abuts the recurrent laryngeal nerve or trachea, extrathyroidal extension or cN1/M1 is present, high-grade cytology/molecular profile is identified, or reliable follow-up is unavailable.

Before: Suggesting that every thyroid tumor <=1.0 cm is suitable for active surveillance or, conversely, mandating immediate surgery in all low-risk T1a microcarcinomas.

Now: Shared decision-making between structured active ultrasound surveillance (neck US every 6 months for 1–2 years, then annually) and initial thyroid lobectomy in strictly eligible patients; exclude active surveillance if subcapsular tumor abuts the recurrent laryngeal nerve or trachea, extrathyroidal extension or cN1/M1 is present, high-grade cytology/molecular profile is identified, or reliable follow-up is unavailable.

Adults with biopsy-proven intrathyroidal T1a (<=1.0 cm) cN0 papillary microcarcinoma. Outcomes rated in the matrix: tumor enlargement (>=3 mm), novel nodal metastasis, and disease-specific survival.

In the Kuma Hospital prospective cohort (>3,000 patients), 10-year tumor enlargement (>=3 mm) was ~6%–8% and novel nodal metastasis was 1.5%–3.8% (lower in patients >=60 years [<4%] than in patients <40 years), with 0% distant metastasis or thyroid cancer mortality when rescue surgery was triggered by progression (>=3 mm growth, new nodal metastasis, or patient preference). Convert to surgery for tumour growth ≥3 mm in any dimension, new cervical nodal metastasis, posterior/extrathyroidal growth, or patient preference (§5.2).

• 2025 ATA Differentiated Thyroid Cancer Guidelines (PMID 40844370)
• Kuma Hospital Cohort — Miyauchi et al., Thyroid 2018 (PMID 29092634)
• MSKCC Cohort — Tuttle et al., JAMA Otolaryngol Head Neck Surg 2017 (PMID 28859191)
• 2020 ETA Thermal Ablation Guideline — Mauri, Hegedüs, Bernardi et al., Eur Thyroid J 2020 (PMID 32903999)